All In Biotech

Drug Trial Radar · NCT05490446

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

87

Actual

Start

Nov 7, 2022

Primary completion

Mar 17, 2026

Study completion Mar 2029

Sponsor

Lead sponsor
Agios Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Aug 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.

Conditions

  • Myelodysplastic Syndromes

Interventions

  • TebapivatDrug

    Tebapivat Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2a: Proportion of Participants With Hemoglobin (Hb) ResponseTime frame: Baseline, Week 8 through Week 16
  2. Phase 2a: Proportion of Participants With Transfusion Independence During the Core PeriodTime frame: Up to 16 weeks
  3. Phase 2b: Proportion of Participants With Transfusion IndependenceTime frame: Up to 24 weeks

Locations

45 sites in 13 countries. Site status is shown where the registry gives one.

  • Innovative Clinical Research Institute Whittier

    Lakewood, California

  • David Geffen School of Medicine at UCLA

    Los Angeles, California

  • Emad Ibrahim, MD, Inc.

    Redlands, California

  • Smilow Cancer Hospital at Yale New Haven

    New Haven, Connecticut

  • Mayo Clinic Jacksonville - PPDS

    Jacksonville, Florida

  • Edward H. Kaplan MD & Associates

    Skokie, Illinois

  • Washington University School of Medicine

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center

    Long Island City, New York

  • Duke Adult Blood and Marrow Clinic

    Durham, North Carolina

  • Monash Health, Monash Medical Centre

    Clayton, Victoria, Australia

  • Ordensklinikum Linz GmbH Elisabethinen

    Linz, Upper Austria, Austria

  • Fakultni nemocnice Ostrava

    Ostrava, Czechia

  • CHRU Lille

    Lille, France

  • Hôpital Saint Louis

    Paris, France

  • Hôpital de La Conception

    Marseille, Bouches-du-Rhône, France

  • CHU Angers

    Angers, Maine-et-Loire, France

  • Medizinische Hochschule Hannover

    Hanover, Lower Saxony, Germany

  • Universitatsklinikum Dusseldorf

    Düsseldorf, North Rhine-Westphalia, Germany

  • Universitatsklinikum Leipzig

    Leipzig, Saxony, Germany

  • University Hospital of Alexandroupolis

    Alexandroupoli, Greece

  • Attikon University General Hospital

    Athens, Greece

  • University General Hospital of Patras

    Pátrai, Greece

  • Hippokration Hospital

    Thessaloniki, Greece

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Tel Aviv Sourasky Medical Center PPDS

    Tel Aviv, Israel

  • Fondazione PTV Policlinico Tor Vergata

    Roma, Italy

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, Italy

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    Pavia, Lombardy, Italy

  • Istituto Clinico Humanitas

    Rozzano, Lombardy, Italy

  • Azienda Ospedaliera Ordine Mauriziano di Torino

    Turin, Piedmont, Italy

  • MTZ Clinical Research Powered by PRATIA - PPDS

    Warsaw, Masovian Voivodeship, Poland

  • Pratia Onkologia Katowice - PRATIA - PPDS

    Katowice, Silesian Voivodeship, Poland

  • SPZOZ MiSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie

    Olsztyn, Warmian-Masurian Voivodeship, Poland

  • Kyungpook National University Hospital

    Daegu, South Korea

  • Asan Medical Center - PPDS

    Seoul, South Korea

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea

  • C.H. Regional Reina Sofia - PPDS

    Córdoba, Spain

  • Hospital Universitario La Paz - PPDS

    Madrid, Spain

  • Hospital Universitario HM Sanchinarro - CIOCC

    Madrid, Spain

  • Complejo Asistencial Universitario de Salamanca - H. Clinico

    Salamanca, Spain

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.